ES2257666T3 - Uso de (3-(2-etilfenil)-5-metoxifenil)-1h-(1,2,4)-triazol para el tratamiento de enfermedades autoinmunes. - Google Patents

Uso de (3-(2-etilfenil)-5-metoxifenil)-1h-(1,2,4)-triazol para el tratamiento de enfermedades autoinmunes.

Info

Publication number
ES2257666T3
ES2257666T3 ES03720879T ES03720879T ES2257666T3 ES 2257666 T3 ES2257666 T3 ES 2257666T3 ES 03720879 T ES03720879 T ES 03720879T ES 03720879 T ES03720879 T ES 03720879T ES 2257666 T3 ES2257666 T3 ES 2257666T3
Authority
ES
Spain
Prior art keywords
cells
patients
ethylphenyl
compound
ipp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03720879T
Other languages
English (en)
Spanish (es)
Inventor
L. Sigma-Tau Ind. Farm. Riunite S.P.A. Battistini
G. Sigma-Tau Ind. Farm. Riunite S.P.A. Borsellino
R. Sigma-Tau Ind. Farm. Riunite S.P.A. De Santis
P. Sigma-Tau Ind. Farm. Riunite S.P.A. Carminati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2257666T3 publication Critical patent/ES2257666T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES03720879T 2002-05-03 2003-04-15 Uso de (3-(2-etilfenil)-5-metoxifenil)-1h-(1,2,4)-triazol para el tratamiento de enfermedades autoinmunes. Expired - Lifetime ES2257666T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/137,699 US6797722B2 (en) 2002-05-03 2002-05-03 Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
US137699 2002-05-03

Publications (1)

Publication Number Publication Date
ES2257666T3 true ES2257666T3 (es) 2006-08-01

Family

ID=29269138

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03720879T Expired - Lifetime ES2257666T3 (es) 2002-05-03 2003-04-15 Uso de (3-(2-etilfenil)-5-metoxifenil)-1h-(1,2,4)-triazol para el tratamiento de enfermedades autoinmunes.

Country Status (15)

Country Link
US (2) US6797722B2 (https=)
EP (1) EP1501505B1 (https=)
JP (1) JP2005529904A (https=)
KR (1) KR20040111491A (https=)
AT (1) ATE315935T1 (https=)
AU (1) AU2003224453A1 (https=)
CA (1) CA2483904A1 (https=)
DE (1) DE60303296T2 (https=)
DK (1) DK1501505T3 (https=)
ES (1) ES2257666T3 (https=)
MX (1) MXPA04010785A (https=)
PL (1) PL374252A1 (https=)
PT (1) PT1501505E (https=)
TW (1) TWI284532B (https=)
WO (1) WO2003092681A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma
EP1921073A1 (en) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379155A (en) * 1979-06-11 1983-04-05 Gruppo Lepetit S.P.A. 3,5-Disubstituted-1H-1,2,4-triazole derivatives
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
DE3808283A1 (de) * 1988-03-12 1989-09-21 Boehringer Ingelheim Kg Neue 3,4,5-substituierte 4h-1,2,4-triazole, ihre herstellung und verwendung
US4895872A (en) * 1989-03-15 1990-01-23 Cetus Corporation Immunosupressive analogues and derivatives of succinylacetone
US5273979A (en) * 1991-08-01 1993-12-28 Merck & Co., Inc. C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
AU4385696A (en) * 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues
ATE298740T1 (de) * 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
IT1292092B1 (it) * 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
EP1099695A1 (en) * 1999-11-09 2001-05-16 Laboratoire Theramex S.A. 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DE60303296T2 (de) 2006-08-17
PL374252A1 (en) 2005-10-03
EP1501505B1 (en) 2006-01-18
EP1501505A1 (en) 2005-02-02
JP2005529904A (ja) 2005-10-06
CA2483904A1 (en) 2003-11-13
PT1501505E (pt) 2006-05-31
US20050026980A1 (en) 2005-02-03
MXPA04010785A (es) 2005-03-07
DK1501505T3 (da) 2006-05-22
US6797722B2 (en) 2004-09-28
AU2003224453A1 (en) 2003-11-17
ATE315935T1 (de) 2006-02-15
TW200418464A (en) 2004-10-01
DE60303296D1 (de) 2006-04-06
WO2003092681A1 (en) 2003-11-13
KR20040111491A (ko) 2004-12-31
TWI284532B (en) 2007-08-01
US20030207931A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
Abbas et al. Functional diversity of helper T lymphocytes
Haslett et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
Abdel-Moneim et al. The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus
Beeton et al. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation
Germann et al. lnterleukin-12
Ma et al. Tumor necrosis factor α blockade exacerbates murine psoriasis‐like disease by enhancing Th17 function and decreasing expansion of Treg cells
ES2586837T3 (es) Método para la expansión in vivo de linfocitos T reguladores
Wittig et al. The gut as an organ of immunology
Yong et al. Role and mechanisms of CD4+ CD25+ regulatory T cells in the induction and maintenance of transplantation tolerance
Moller et al. Inhibition of IL-12 production by thalidomide
Stallmach et al. An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn’s disease and experimental colitis in vivo
Fantus et al. Evolving perspectives of mTOR complexes in immunity and transplantation
Min et al. Decreased production of interleukin-12 and interferon-? is associated with renal involvement in systemic lupus erythematosus
KR0159046B1 (ko) 포유류의 자기면역 포도막망막염의 치료 또는 예방방법
Jiang et al. MOG35–55 iv suppresses experimental autoimmune encephalomyelitis partially through modulation of Th17 and JAK/STAT pathways
Di Rosa et al. Lack of Th2 cytokine increase during spontaneous remission of experimental allergic encephalomyelitis
ES2257666T3 (es) Uso de (3-(2-etilfenil)-5-metoxifenil)-1h-(1,2,4)-triazol para el tratamiento de enfermedades autoinmunes.
LAUNOIS et al. Setting in motion the immune mechanisms underlying genetically determined resistance and susceptibility to infection with Leishmania major
Gessner et al. Stimulation of B-cell lymphopoiesis by interleukin-7 leads to aggravation of murine leishmaniasis
Qiao et al. T cell receptor repertoire and mitotic responses of lamina propria T lymphocytes in inflammatory bowel disease
Phillips et al. Effect of DAB389IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats
Jiang et al. Splenic CD8+ T cells secrete TGF-β1 to exert suppression in mice with anterior chamber-associated immune deviation
Coffman et al. Reversal of polarized T helper 1 and T helper 2 cell populations in murine leishmaniasis
Glatigny et al. Treatment of collagen‐induced arthritis by Natura‐α via regulation of Th‐1/Th‐17 responses
Hori et al. Alloantigen-specific prolongation of allograft survival in recipient mice treated by alloantigen immunization following ultraviolet-B irradiation